Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A mouse model of melanoma driven by oncogenic KRAS.

Literature DB >> 20516123

A mouse model of melanoma driven by oncogenic KRAS.

Carla Milagre¹, Nathalie Dhomen, Felipe C Geyer, Robert Hayward, Maryou Lambros, Jorge S Reis-Filho, Richard Marais.

Abstract

The small G-protein NRAS is mutated in 22% of human melanomas, whereas the related proteins KRAS and HRAS are mutated in only 2% and 1% of melanomas, respectively. We have developed a mouse model of melanoma in which Cre recombinase/LoxP technology is used to drive inducible expression of (G12V)KRAS in the melanocytic lineage. The mice develop skin hyperpigmentation, nevi, and tumors that bear many of the cardinal histopathology features and molecular characteristics of human melanoma. These tumors invade and destroy the underlying muscles and cells derived from them can grow as subcutaneous tumors and colonize the lungs of nude mice. These data establish that oncogenic KRAS can be a founder event in melanomagenesis. Copyright 2010 AACR.

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2010 PMID： 20516123 PMCID： PMC2896549 DOI： 10.1158/0008-5472.CAN-09-4254

Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701

26 in total

1. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors: Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal: Cell Date: 2004-03-19 Impact factor: 41.582

2. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene.

Authors: R Meuwissen; S C Linn; M van der Valk; W J Mooi; A Berns
Journal: Oncogene Date: 2001-10-04 Impact factor: 9.867

3. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Authors: N Bardeesy; B C Bastian; A Hezel; D Pinkel; R A DePinho; L Chin
Journal: Mol Cell Biol Date: 2001-03 Impact factor: 4.272

4. K-ras is essential for the development of the mouse embryo.

Authors: K Koera; K Nakamura; K Nakao; J Miyoshi; K Toyoshima; T Hatta; H Otani; A Aiba; M Katsuki
Journal: Oncogene Date: 1997-09-04 Impact factor: 9.867

5. K-ras is an essential gene in the mouse with partial functional overlap with N-ras.

Authors: L Johnson; D Greenbaum; K Cichowski; K Mercer; E Murphy; E Schmitt; R T Bronson; H Umanoff; W Edelmann; R Kucherlapati; T Jacks
Journal: Genes Dev Date: 1997-10-01 Impact factor: 11.361

Review 6. ras oncogenes in human cancer: a review.

Authors: J L Bos
Journal: Cancer Res Date: 1989-09-01 Impact factor: 12.701

7. Oncogenic Braf induces melanocyte senescence and melanoma in mice.

Authors: Nathalie Dhomen; Jorge S Reis-Filho; Silvy da Rocha Dias; Robert Hayward; Kay Savage; Veronique Delmas; Lionel Larue; Catrin Pritchard; Richard Marais
Journal: Cancer Cell Date: 2009-04-07 Impact factor: 31.743

8. Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus.

Authors: Artur Zembowicz; J Aidan Carney; Martin C Mihm
Journal: Am J Surg Pathol Date: 2004-01 Impact factor: 6.394

9. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter.

Authors: M B Powell; P Hyman; O D Bell; A Balmain; K Brown; D Alberts; G T Bowden
Journal: Mol Carcinog Date: 1995-02 Impact factor: 4.784

Review 10. Targeting RAS signalling pathways in cancer therapy.

Authors: Julian Downward
Journal: Nat Rev Cancer Date: 2003-01 Impact factor: 60.716

33 in total

Review 1. A brief history of melanoma: from mummies to mutations.

Authors: Vito W Rebecca; Vernon K Sondak; Keiran S M Smalley
Journal: Melanoma Res Date: 2012-04 Impact factor: 3.599

2. Transcriptome analysis to identify the Ras and Rap1 signal pathway genes involved in the response of TM3 Leydig cells exposed to zearalenone.

Authors: Mingyang Wang; Nan Wang; Jingjing Tong; Jiawen Pan; Miao Long; Peng Li
Journal: Environ Sci Pollut Res Int Date: 2018-09-06 Impact factor: 4.223

3. The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors: Keith Duffy; Douglas Grossman
Journal: J Am Acad Dermatol Date: 2012-07 Impact factor: 11.527

10. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.

Authors: P Dietrich; S Kuphal; T Spruss; C Hellerbrand; A K Bosserhoff
Journal: Oncogene Date: 2017-10-23 Impact factor: 9.867